ARQT — Arcutis Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787306 ·
Last close
$26.86
Market Cap
$3.36B
52W High
$29.84
52W Low
$19.30
ADV30
1,605,747
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 105,398,000 | 95,614,000 | -9,089,000 | -11,295,000 | 460,003,000 | 34,762,000 | 270,355,000 |
| Dec 2025 | 129,503,000 | 117,815,000 | 18,387,000 | 17,395,000 | 432,973,000 | 42,907,000 | 243,494,000 |
| Sep 2025 | 99,219,000 | 90,534,000 | 8,526,000 | 7,410,000 | 370,977,000 | 47,120,000 | 212,904,000 |
| Jun 2025 | 81,504,000 | 74,012,000 | -14,611,000 | -15,886,000 | 352,433,000 | 72,740,000 | 213,459,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,625,000
Investing CF
$-30,253,000
Financing CF
$6,973,000
CapEx
$-15,686,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,138,084,000
Inventory
$22,634,000
Receivables
$146,229,000
ST Investments
$178,075,000
EBIT TTM
$-2,887,000
Pretax Income TTM
$-14,970,000
Interest Exp TTM
$12,083,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$415,624,000
EBITDA
$5,463,000
Free Cash Flow
$3,531,000
Enterprise Value
$3,250,410,496
Total Cash
$224,000,000
Total Debt
$114,671,000
Shares Out
125,083,374
Trailing EPS
$-0.02
Book Value
$1.52
ROE
-1.4%
ROA
0.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,072,000 | -12,227,000 | -16,141,000 | 432,973,000 | 243,494,000 | — | -5,625,000 |
| Dec 2024 | 196,542,000 | -128,397,000 | -140,039,000 | 348,889,000 | 191,348,000 | — | -112,158,000 |
| Dec 2023 | 59,606,000 | -241,101,000 | -262,140,000 | 341,365,000 | 252,698,000 | — | -247,057,000 |
| Dec 2022 | 3,686,000 | -301,627,000 | -311,458,000 | 449,274,000 | 239,693,000 | — | -257,715,000 |
TTM Snapshot
Revenues TTM
$83,589,000
NetIncome TTM
$-250,991,000
OpCashFlow TTM
$0
Assets (Latest)
$348,889,000
Forward EPS
$1.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLX | Telix Pharmaceuticals Ltd | $3.35B | $9.89 | — |
| TLPPF | Telix Pharmaceuticals Ltd | $3.34B | $9.86 | — |
| GRTX | Galera Therapeutics, Inc. | $3.38B | $16.28 | — |
| GPCR | Structure Therapeutics Inc. | $3.41B | $48.04 | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.42B | $35.50 | — |
News headlines (Yahoo Finance, 1h cache)
Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight
2026-07-31 15:10 · Yahoo
Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation
2026-07-31 06:08 · Yahoo
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
2026-07-30 14:00 · Yahoo
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2026-07-29 14:00 · Yahoo
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet
2026-07-21 13:55 · Yahoo
Arcutis Expands Board of Directors with Appointment of Chris Peetz
2026-07-16 13:00 · Yahoo
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
2026-07-15 20:00 · Yahoo
Attovia Therapeutics Appoints John W. Smither to Board of Directors
2026-07-15 12:30 · Yahoo
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
2026-07-09 17:37 · Yahoo
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
2026-07-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.